Learn more about the Agency's resources to support medicine development:
Learn more about how EMA interacts with academia.
Featured information for academics and researchers
EU agencies promoting a One Health approach
EMA and other scientific EU agencies responsible for human, animal health and environmental protection have established a task force to coordinate activities and share information, promoting a joined-up One Health approach. A paper is available containing more details.
New online platform for PRIME eligibility requests
As of 10 July 2023, medicine developers should use EMA’s IRIS platform to submit a PRIME eligibility request. Guidance is available on how to register for IRIS and use it for PRIME eligibility requests and other procedures
Bacteriophages as veterinary medicines: guideline now available
A CVMP guideline is available on the quality, safety and efficacy of bacteriophages as veterinary medicines. These viruses that infect bacteria could substitute or complement the use of antibiotics in animals. The guideline sets out the regulatory and scientific requirements for veterinary medicines designed for phage therapy and composed of bacteriophages
EMA communication activities
We asked stakeholders for feedback on our communication activities in a survey in 2022 and captured the results in a newly-published report. The findings help us set targets, address areas for improvement and measure progress. For example, we are already adapting our messaging to better suit audience needs and are creating more visuals based on survey insights. We thank all respondents for their feedback.
Call for clinical-oncology scientists to join EMA / HMA pilot on participation in medicine regulation
EMA and HMA are inviting clinical-oncology and haemato-oncology scientists to apply for a pilot project aiming to develop their expertise in human medicine regulation. The pilot offers free webinars providing an understanding of the basic principles for this field. Participation is possible until May 2024.
Engaging with academia: action plan for 2021 to 2023
EMA's academia collaboration matrix action plan sets out how EMA intends to create closer ties with academics and researchers in the next two and a half years. It lists actions in five areas: regulatory science and partnerships, innovation and support to academia, communication, events strategy, and training.
Fee waiver for protocol assistance (scientific advice for orphan medicines)
Applicants from the academic sector can receive free protocol assistance for developing orphan medicines.
European medicines agencies network strategy to 2025
The strategy sets out how the network will continue to enable the supply of safe and effective medicines, in the face of developments in science, medicine, digital technologies, globalisation and emerging health threats, such as the COVID-19 pandemic.
Publications of interest
EMA's 2022 annual report
Navigate through the digital report to view interviews, short videos and an interactive timeline of the Agency’s main activities in 2022. Read the traditional PDF version to see additional figures and statistics on EMA's regulatory procedures and activities.
Video: Working for every patient in Europe
Watch our short video for a quick and easy explanation of who EMA is and what it does. (video in English, with subtitles in 24 different languages).
EMA’s individual stakeholder database: patients, consumers, healthcare professionals and academia - Frequently asked questions
English (EN)
(135.87 KB - PDF)View